| Objective:This study detects mRNA and protein expression levels of B cell activating factor of the TNF family to research the characteristics and clinical significance,and clinical observation of high-dose dexamethasone treatment in ITP patients,combined with BAFFand platelet count.Analysis the difference between treatment of high-dose dexamethasone and standard-dose glucocorticoid.to provide more evidence for the pathogenesis,efficacy evaluation.prognosis of ITP.Methods:Experimental group:experimental group 1 (high-dose dexamethasone treatment group) contain 24 patients with ITP patients, experimental group 2(standard-dose glucocorticoid treatment group) contain 22 patients with ITP patients,10 cases of experimental group 3 (Group other causes thrombocytopenia),negative control group of 20 patiengs(all healthy volunteers).Detect the expression of BAFF in patients with different treatment options by RT-PCR and ELISA assay before and after treatments.Results:1. the expression of BAFF before and after treatment in ITP patients①he expression of BAFF mRNA in patients and the negative control group:the expression of BAFF of 46 cases before the treatment was 4.94±0.89, the expression of BAFF of 46 cases after treatment was2.88±0.66,20 cases of negative controls the expression of BAFF was2.91±0.66,10 cases of other causes thrombocytopenia was 4.81±0.78. BAFF levels before treatment in patients with ITP was significantly higher than that after treatment(P<0.01).Between BAFF levels before treatment and group of other causes thrombocytopenia,there was no significant difference(P>0.05). The level of BAFF after treatment with the negative control group no significant difference. The expression of BAFF was significantly decreased after treatment(P< 0.05).②he expression of BAFF protein in patients and the negative control group:the expression of BAFF of 46 cases before the treatment was 721.03±117.70 pg/ml, the expression of BAFF of 46 cases after treatment was548.57±88.33 pg/ml,20 cases of negative controls the expression of BAFF was 512.50±86.91 pg/ml,10 cases of other causes thrombocytopenia was 782.00±138.08 pg/ml.BAFF levels before treatment in patients with ITP was significantly higher than that after treatment(P<0.01).Between BAFF levels before treatment and group of other causes thrombocytopenia,there was no significant difference(P>0.05).The level of BAFF after treatment with the negative control group no significant difference. The expression of BAFF was significantly decreased after treatment(P<0.05).2.The expression of BAFF before and after treatment of high-dose dexamethasone①he expression of BAFF mRNA in patients in high-dose dexamethasone group and the negative control group:the expression of BAFF of 24 cases before received high-dose dexamethasone for the treatment was 5.06±0.80, the expression of BAFF of 24 cases after received high-dose dexamethasone for the treatment was2.83±0.79,20 cases of negative controls the expression of BAFF was2.91±0.66.The level of BAFF,receiving high-dose dexamethasone in patients before treatment, was significantly higher than the negative control group.And after treatment compared with the negative control group no significant difference. The expression of BAFF was significantly decreased after treatment(P<0.05).②he expression of BAFF protein in patients in high-dose dexamethasone group and the negative control group:the expression of BAFF of 24 cases before received high-dose dexamethasone for the treatment was 695.19±107.55pg/ml, the expression of BAFF of 24 cases after received high-dose dexamethasone for the treatment was538.25±93.43pg/ml,20 cases of negative controls the expression of BAFF was 512.50±86.91 pg/ml.The level of BAFF,receiving high-dose dexamethasone in patients before treatment, was significantly higher than the negative control group.And after treatment compared with the negative control group no significant difference. The expression of BAFF was significantly decreased after treatment(P< 0.05).3.The expression of BAFF before and after treatment of standard-dose glucocorticoid①the expression of BAFF mRNA in patients in standard-dose glucocorticoid group and the negative control group:the expression of BAFF of 22 cases before received standard-dose glucocorticoid for the treatment was 4.82±0.98. the expression of BAFF of 22 cases after received standard-dose glucocorticoid for the treatment was2.93±0.50,20 cases of negative controls the expression of BAFF was2.91±0.66.The level of BAFRreceiving standard-dose glucocorticoid in patients before treatment, was significantly higher than the negative control group.And after treatment with the negative control group no significant difference. The expression of BAFF was significantly decreased after treatment(P<0.05).②he expression of BAFF protein in patients in standard-dose glucocorticoid group and the negative control group:the expression of BAFF of 22 cases before received standard-dose glucocorticoid for the treatment was 749.22±124.18pg/ml, the expression of BAFF of 22 cases after received standard-dose glucocorticoid for the treatment was559.83±83.08pg/ml.20 cases of negative controls the expression of BAFF was 512.50±86.91pg/ml.The level of BAFF.receiving standard-dose glucocorticoid in patients before treatment, was significantly higher than the negative control group.And after treatment with the negative control group no significant difference. The expression of BAFF was significantly decreased after treatment(P< 0.05).③etect expression of BAFF protein and mRNA for 1 case of the standard-dose glucocorticoid therapy in patients with newly diagnosed ITP.,in the day of the firsU the 7th day,the 14th day,the 21th day. the 28th day. Two methods are prompted BAFF expression decreased. In 28th day,BAFF expression and the negative control group difference was not statistically significant.4.The expression of BAFF was no significant difference.comparing the receiving high-dose dexamethasone treatment of patients to patients receiving standard-dose glucocorticoid therapy(P>0.05).5.BAFF expression in the two experimental groups was little correlate with platelet count. Conclusions:1.BAFF expression of mRNA and protein in ITP patients was significantly increased than normal,decreased after treatment,related with disease activity.2.Block the expression of BAFF in ITP may become a new target for treatment of ITP.3.High-dose dexamethasone treatment of ITP was high reactivity and side effects, in terms of BAFF expression and platelet count with standard doses of glucocorticoid therapy was no significant difference. |
PDF Full Text Request